Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
MRNA

MRNA - Moderna Inc Stock Price, Fair Value and News

96.44USD-3.00 (-3.02%)Market Closed
Watchlist

Market Summary

USD96.44-3.00
Market Closed
-3.02%

MRNA Alerts

  • 2 major insider sales recently.

MRNA Stock Price

View Fullscreen

MRNA RSI Chart

MRNA Valuation

Market Cap

36.8B

Price/Earnings (Trailing)

-7.82

Price/Sales (Trailing)

5.38

EV/EBITDA

-9.5

Price/Free Cashflow

-9.63

MRNA Price/Sales (Trailing)

MRNA Profitability

EBT Margin

-57.56%

Return on Equity

-34.03%

Return on Assets

-25.58%

Free Cashflow Yield

-10.38%

MRNA Fundamentals

MRNA Revenue

Revenue (TTM)

6.8B

Rev. Growth (Yr)

-44.71%

Rev. Growth (Qtr)

53.52%

MRNA Earnings

Earnings (TTM)

-4.7B

Earnings Growth (Yr)

-85.19%

Earnings Growth (Qtr)

105.98%

Breaking Down MRNA Revenue

Last 7 days

1.1%

Last 30 days

-16.6%

Last 90 days

15.6%

Trailing 12 Months

-47.8%

How does MRNA drawdown profile look like?

MRNA Financial Health

Current Ratio

3.42

MRNA Investor Care

Buy Backs (1Y)

0.78%

Diluted EPS (TTM)

-12.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202315.1B10.7B9.1B6.8B
202222.6B23.0B21.4B19.3B
20212.7B7.0B11.8B18.5B
202052.2M106.1M246.1M803.0M
2019122.1M106.3M81.6M60.2M
2018204.5M192.3M191.6M135.1M
2017132.8M157.1M181.5M205.8M
2016000108.4M

Tracking the Latest Insider Buys and Sells of Moderna Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 16, 2024
bancel stephane
sold
-2,342,100
88.8808
-26,351
chief executive officer
Feb 16, 2024
hoge stephen
sold
-936,981
88.8808
-10,542
president
Feb 14, 2024
hoge stephen
acquired
-
-
22,694
president
Feb 14, 2024
bancel stephane
acquired
-
-
56,736
chief executive officer
Feb 12, 2024
hoge stephen
sold
-26,213
86.2292
-304
president
Feb 09, 2024
hoge stephen
acquired
-
-
522
president
Jan 16, 2024
hoge stephen
sold
-1,558,500
103
-15,000
president
Jan 08, 2024
mock james m
sold
-84,730
109
-772
chief financial officer
Jan 05, 2024
mock james m
acquired
-
-
1,452
chief financial officer
Dec 27, 2023
hoge stephen
sold
-4,500,450
100
-45,000
president

1–10 of 50

Which funds bought or sold MRNA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 22, 2024
Scarborough Advisors, LLC
new
-
6,085
6,085
-%
Feb 21, 2024
CHELSEA COUNSEL CO
reduced
-26.81
-176,350
420,873
0.22%
Feb 21, 2024
V-Square Quantitative Management LLC
added
36.35
59,199
248,426
0.04%
Feb 21, 2024
Raleigh Capital Management Inc.
new
-
3,482
3,482
-%
Feb 20, 2024
Aurora Investment Counsel
sold off
-100
-511,596
-
-%
Feb 20, 2024
Pacific Center for Financial Services
unchanged
-
-99.00
2,387
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
reduced
-25.92
-44,283,000
110,141,000
0.01%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
reduced
-16.46
-33,520
137,838
0.01%
Feb 16, 2024
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main
reduced
-32.47
-6,300,200
11,709,300
0.01%
Feb 16, 2024
CIM INVESTMENT MANAGEMENT INC
sold off
-100
-217,322
-
-%

1–10 of 39

Are Funds Buying or Selling MRNA?

Are funds buying MRNA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own MRNA
No. of Funds

Unveiling Moderna Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
8.89%
33,906,974
SC 13G/A
Feb 07, 2024
bancel stephane
7.8%
30,384,866
SC 13G/A
Jan 29, 2024
blackrock inc.
6.6%
25,301,057
SC 13G/A
Jan 29, 2024
baillie gifford & co
11.97%
45,654,527
SC 13G/A
Feb 10, 2023
bancel stephane
7.41%
29,151,802
SC 13G/A
Feb 09, 2023
vanguard group inc
7.10%
27,282,173
SC 13G/A
Feb 01, 2023
blackrock inc.
6.8%
26,115,224
SC 13G/A
Jan 19, 2023
baillie gifford & co
11.66%
44,786,746
SC 13G/A
Feb 14, 2022
bancel stephane
7.64%
31,538,184
SC 13G/A
Feb 14, 2022
flagship ventures fund iv general partner llc
2.8%
11,460,435
SC 13G/A

Recent SEC filings of Moderna Inc

View All Filings
Date Filed Form Type Document
Feb 23, 2024
10-K
Annual Report
Feb 23, 2024
4
Insider Trading
Feb 23, 2024
S-8
Employee Benefits Plan
Feb 22, 2024
144
Notice of Insider Sale Intent
Feb 22, 2024
8-K
Current Report
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
144
Notice of Insider Sale Intent
Feb 16, 2024
144
Notice of Insider Sale Intent
Feb 13, 2024
4
Insider Trading

Peers (Alternatives to Moderna Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
36.8B
6.8B
-16.59% -47.80%
-7.82
5.38
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.9B
1.8B
-23.99% -31.71%
-45.13
10.87
76.23% 61.08%
17.2B
2.3B
-4.89% -18.90%
116.89
7.44
15.05% 75.21%
13.6B
3.7B
-7.62% -26.87%
22.76
3.68
8.87% 75.42%
MID-CAP
8.1B
272.9M
-2.06% 34.31%
-13.4
29.75
141.38% 4.43%
6.0B
-
-3.85% 226.12%
-9.54
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.34
6.44
23.54% 31.53%
3.9B
240.7M
-19.08% -10.99%
-13.19
16.26
-1.03% -92.09%
3.7B
270.6M
8.92% 47.81%
-15.63
13.81
440.80% -27.84%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
24.15
4.3
81.69% -7.29%
629.6M
1.0B
-9.17% -57.89%
-1.15
0.6
-43.15% 58.48%
179.0M
4.9M
-14.18% -58.18%
-1.09
36.62
-57.57% 50.48%
114.7M
881.7K
289.54% 381.25%
-2.42
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Moderna Inc News

Latest updates
Seeking Alpha16 hours ago
InvestorsObserver25 hours ago
StockNews.com20 Feb 202412:02 pm

Moderna Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue53.5%2,811,0001,831,000344,0001,862,0005,084,0003,364,0004,749,0006,066,0007,211,0004,969,0004,354,0001,937,000571,000157,00067,0008,00014,05517,04613,08316,02535,421
Costs and Expenses-27.0%2,805,0003,843,0002,211,0002,228,0003,504,0002,198,0002,302,0001,839,0001,801,0001,411,0001,292,000671,000846,000392,000189,000139,000-----
Operating Expenses--------------393,027188,478139,251144,611147,810156,792157,666188,452
  S&GA Expenses6.3%470,000442,000332,000305,000375,000278,000211,000268,000201,000168,000121,00077,00079,00048,00037,00024,00026,08728,17328,48727,25338,023
  R&D Expenses21.2%1,406,0001,160,0001,148,0001,131,0001,211,000820,000710,000554,000648,000521,000421,000401,000759,000344,000152,000115,000117,645119,637128,305130,413150,429
EBITDA Margin-139.5%-0.52*-0.22*0.11*0.36*0.52*0.64*0.70*0.73*0.73*0.66*0.56*0.25*---------
Income Taxes-108.8%-147,0001,672,000-369,000-384,000190,000174,000277,000572,000542,000219,000283,00039,0002,0001,000---474-178-324-24.00168
Earnings Before Taxes103.6%70,000-1,958,000-1,749,000-305,0001,655,0001,217,0002,474,0004,229,0005,410,0003,552,0003,063,0001,260,000-271,000-232,000-117,000-124,000-123,743-123,393-135,264-132,600-141,258
EBT Margin-122.8%-0.58*-0.26*0.08*0.33*0.50*0.62*0.68*0.72*0.72*0.64*0.54*0.23*---------
Net Income106.0%217,000-3,630,000-1,380,00079,0001,465,0001,043,0002,197,0003,657,0004,868,0003,333,0002,780,0001,221,000-273,000-233,000-117,000-124,000-123,269-123,215-134,940-132,576-141,426
Net Income Margin-81.2%-0.69*-0.38*0.11*0.32*0.43*0.55*0.61*0.65*0.66*0.60*0.50*0.22*---------
Free Cashflow123.1%402,000-1,740,000-1,149,000-1,338,0001,570,000163,000217,0002,631,0003,190,0003,177,0004,033,0002,936,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-5.3%18,42619,45021,88424,12525,85826,05626,04327,60924,66920,92316,15312,6947,3374,6513,4862,0681,5891,5911,6851,8062,020
  Current Assets-4.4%10,32510,79910,59912,12213,43114,29713,56316,35016,07113,42510,96911,7036,2983,5772,7971,2501,1291,0941,0971,1411,563
    Cash Equivalents-0.1%2,9282,9323,8013,4413,2053,0272,8735,0486,8605,5505,6035,4422,6241,5061,762392248174152503670
  Inventory-58.5%2024877157329492,0771,9211,9421,44196564349447.00--------
  Net PPE------------------204209213209
Liabilities-23.7%4,5725,9954,9355,2626,7358,0648,05810,53410,52410,7999,4498,8564,7761,891539427415339347360432
  Current Liabilities-31.2%3,0154,3853,1233,4994,9236,8076,8129,2389,1289,9578,8408,4414,3891,474162135143148162159223
Shareholder's Equity3.0%13,85413,45516,94918,86319,12317,99217,98517,07514,14510,1246,7043,8382,5612,7602,9471,6411,1751,2481,3351,4421,530
  Retained Earnings1.6%13,60613,38917,01918,39918,32016,85515,81213,6159,9585,0901,757-1,023-2,244-1,970-1,740-1,620-1,496-1,369-1,246-1,111-1,006
  Additional Paid-In Capital33.9%3712771937311,1731,4882,4133,6444,2115,0034,9314,8604,8024,7264,6763,2682,6692,6182,5822,5572,538
Shares Outstanding0.3%382381381384385396399402403404401400---------
Float-------48,800---80,800---25,250---3,380--
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations138.9%622-1,600-915-1,2251,6622523042,7633,3103,2764,0632,9711,264893-24.00-106-99.05-107-108-144-91.02
  Share Based Compensation2.6%79.0077.0074.0075.0062.0070.0050.0044.0037.0040.0035.0030.0026.0022.0025.0020.0020.0021.0021.0018.0032.00
Cashflow From Investing-168.2%-5387891,9442,011-1,048945-1,152-3,921-1,138-3,327-3,878-180-190-1,17913.00-316130113-246-11.766.00
Cashflow From Financing-87.9%-109-58.00-668-542-438-1,041-1,327-642-873-2.00-24.0026.0044.0030.001,38157832.0016.004.000.00576
  Buy Backs100.0%--1.006285264021,0061,298623857------------

MRNA Income Statement

2023-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue:    
Total revenue$ 1,831$ 3,364$ 4,037$ 14,179
Operating expenses:    
Cost of sales2,2411,1003,7643,498
Research and development1,1608203,4392,084
Selling, general and administrative4422781,079757
Total operating expenses3,8432,1988,2826,339
(Loss) income from operations(2,012)1,166(4,245)7,840
Interest income10558318113
Other expense, net(51)(7)(85)(33)
(Loss) income before income taxes(1,958)1,217(4,012)7,920
Provision for income taxes1,6721749191,023
Net (loss) income$ (3,630)$ 1,043$ (4,931)$ 6,897
(Loss) earnings per share:    
Basic (in usd per share)$ (9.53)$ 2.67$ (12.89)$ 17.41
Diluted (in usd per share)$ (9.53)$ 2.53$ (12.89)$ 16.46
Weighted average common shares used in calculation of (loss) earnings per share:    
Basic (in shares)381390382396
Diluted (in shares)381412382419
Net product sales    
Revenue:    
Total revenue$ 1,757$ 3,120$ 3,878$ 13,576
Other revenue    
Revenue:    
Total revenue$ 74$ 244$ 159$ 603

MRNA Balance Sheet

2023-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 2,932$ 3,205
Investments4,6416,697
Accounts receivable, net1,8661,385
Inventory487949
Prepaid expenses and other current assets8731,195
Total current assets10,79913,431
Investments, non-current5,2738,318
Property, plant and equipment, net1,9522,018
Right-of-use assets, operating leases765121
Deferred tax assets0982
Other non-current assets661988
Total assets19,45025,858
Current liabilities:  
Accounts payable494487
Accrued liabilities2,2242,101
Deferred revenue1,3722,038
Income taxes payable5648
Other current liabilities239249
Total current liabilities4,3854,923
Deferred revenue, non-current166673
Operating lease liabilities, non-current69792
Financing lease liabilities, non-current575912
Other non-current liabilities172135
Total liabilities5,9956,735
Commitments and contingencies (Note 13)
Stockholders’ equity:  
Preferred stock, par value $0.0001; 162 shares authorized as of September 30, 2023 and December 31, 2022; no shares issued or outstanding at September 30, 2023 and December 31, 202200
Common stock, par value $0.0001; 1,600 shares authorized as of September 30, 2023 and December 31, 2022; 381 and 385 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively00
Additional paid-in capital2771,173
Accumulated other comprehensive loss(211)(370)
Retained earnings13,38918,320
Total stockholders’ equity13,45519,123
Total liabilities and stockholders’ equity$ 19,450$ 25,858
MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration agreement with CARsgen Therapeutics Holdings Limited to evaluate CTO41in combination with mRNA cancer vaccine. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEwww.modernatx.com
 EMPLOYEES3900

Moderna Inc Frequently Asked Questions


What is the ticker symbol for Moderna Inc? What does MRNA stand for in stocks?

MRNA is the stock ticker symbol of Moderna Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Moderna Inc (MRNA)?

As of Fri Feb 23 2024, market cap of Moderna Inc is 36.77 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MRNA stock?

You can check MRNA's fair value in chart for subscribers.

What is the fair value of MRNA stock?

You can check MRNA's fair value in chart for subscribers. The fair value of Moderna Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Moderna Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MRNA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Moderna Inc a good stock to buy?

The fair value guage provides a quick view whether MRNA is over valued or under valued. Whether Moderna Inc is cheap or expensive depends on the assumptions which impact Moderna Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRNA.

What is Moderna Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Feb 23 2024, MRNA's PE ratio (Price to Earnings) is -10.61 and Price to Sales (PS) ratio is 4.03. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRNA PE ratio will change depending on the future growth rate expectations of investors.